京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20793号 / 医博第4293号 / 新制||医||1025(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 妻木 範行, 教授 鈴木 茂彦, 教授 瀬原 淳子 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

No description available.

Indiana University-Purdue University Indianapolis (IUPUI) / LHX3 is a LIM-homeodomain transcription factor that has essential roles in pituitary and nervous system development in mammals. Children who are homozygous for recessive mutations in the LHX3 gene present with combined pituitary hormone deficiency disease (CPHD) characterized by deficits of multiple anterior pituitary hormones. Most LHX3 patients also present with additional defects associated with the nervous system including a characteristic limited head rotation and sometimes deafness. However, of the 10 types of LHX3 mutation described to date, one mutation type (W224ter) does not result in the limited head rotation, defining a new form of the disease. W224ter patients have CPHD but do not have nervous system symptoms. Whereas other mutations in LHX3 cause loss of the entire protein or its activity, the W224ter mutation causes specific loss of the carboxyl terminal of the LHX3 protein—a region that we have shown to contain critical regulatory domains for pituitary gene activation. To better understand the molecular and cellular etiology of CPHD associated with LHX3 gene mutations, I have generated knock-in mice that model the human LHX3 W224ter disease. The resulting mice display marked dwarfism, thyroid disease, female infertility, and reduced male fertility. Immunohistochemistry, real-time quantitative polymerase chain reaction (PCR), and enzyme-linked immunosorbant assays (ELISA) were used to measure hormones and regulatory factor protein and RNA levels, an approach which is not feasible with human patients. We have generated a novel mouse model of human pediatric CPHD. Our findings are consistent with the hypothesis that the actions of the LHX3 factor are molecularly separable in the nervous system and pituitary gland.

京都大学 / 0048 / 新制・課程博士 / 博士(農学) / 甲第22503号 / 農博第2407号 / 新制||農||1077(附属図書館) / 学位論文||R2||N5283(農学部図書室) / 京都大学大学院農学研究科応用生物科学専攻 / (主査)教授 佐藤 健司, 教授 澤山 茂樹, 准教授 豊原 治彦 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM

No description available.

No description available.

No description available.

The pig has similar features to the human in aspects such as physiology, immunology, and organ size. Because of these similarities, genetically modified pigs have been generated for xenotransplantation. Also, when using the pig as a model for human diseases (e.g. cystic fibrosis transmembrane conductance regulator), the pig exhibited similar symptoms to those that human patients present. The main goal of this work was to examine the efficacy of direct injection of the CRISPR/Cas9 system (clustered regularly interspaced short palindromic repeats/ CRISPR associated protein 9) in pigs and to overcome shortcomings that resulted after direct injection into the cytoplasm of developing zygotes. By using direct injection of CRISPR/Cas9 into developing zygotes, we successfully generated fetuses and piglets containing 9 different mutations. The total number of aborted fetuses was 20 and of live piglets was 55. Moreover, one issue that was encountered during the production of mutated pigs was that insertion or deletion (indel) mutations did not always introduce a premature stop codon because it did not interfere with the codon read. As a result of these triplet indel(s) mutations, a hypomorphic phenotype was presented; consequently, the mutated gene was partially functional. To prevent this hypomorphic phenotype, we introduced two sgRNAs to generate an intended deletion that would remove a DNA fragment on the genome by causing two double-strand breaks (DSB) during non-homologous end joining (NHEJ). The injection of two sgRNAs successfully generated the intended deletion on the targeted genes in embryos and live piglets. Results after using intended deletions, in IL2RG mutation pigs, did not show hypomorphic phenotypes even when a premature stop codon was not present. After using the intended deletion approach, function of the targeted genes was completely disrupted regardless of the presence or absence of a premature stop codon. Our next aim was to introduce (i.e. knock-in) a portion of exogenous (donor) DNA sequence into a specific locus by utilizing the homology direct repair (HDR) pathway. Because of the cytotoxicity of the linear form of the donor DNA, the concentration of the injected donor DNA was adjusted. After concentration optimization, four different donor DNA fragments targeting four different genes were injected into zygotes. Efficiency of knock-in was an average of 35%. Another donor DNA was used in this study which is IL2RG-IA donor DNA carried 3kb of exogenous cassette. It showed 15.6% of knock-in efficiency. IL2RG-IA Donor DNA injected embryos were transferred into surrogates, and a total of 7 pigs were born from one surrogate, but none of the 7 were positive for the knock-in. Future experiments need to be developed to optimize this approach. Overall, the direct injection of CRISPR/Cas9 is advantageous in cost, time, and efficiency for large animal production and for biomedical research. However, there are still unsolved challenges (off-targeting effects, low efficiency of knock-in, and monoallelic target mutation) that need to be elucidated for future application in humans and other species. / Doctor of Philosophy / The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system is commonly used to make genetically modified pigs. The CRISPR/Cas9 system can break the DNA on a desired gene region. During the DNA repair process, random DNA base pairs can be inserted or deleted on the broken regions, thus generating a mutation on the desired gene. Scientists have adopted new methods to disrupt genes in many species. One of these new methods is the direct injection of CRISPR/Cas9 into a fertilized oocyte. In our first project, we used direct injection of the CRISPR/Cas9 system into the fertilized one-cell embryo. A total of 55 live pigs and aborted 20 fetuses with specifically disrupted genes were produced for biomedical research model. During these studies, one critical drawback of the direct injection method was encountered. Partial function of the gene was possible. To prevent this problem, two DNA broken regions were generated by the CRISPR/Cas9 system to remove the middle part the DNA by two DNA breaking. This method successfully removed the middle portion of the DNA targeted region in the pig embryos. Embryos injected with the CRISPR/Cas9 system to cut the two specific DNA regions were transplanted into surrogate pigs, and a total of 15 piglets were produced. All 15 pigs confirmed that a specific part of the gene had been removed by two DNA breakage. Also, no function of the desired gene was found in the 15 pigs. The objective of the last experiment was to introduce a specific exogenous DNA sequences into specific region of DNA using the CRISPR/Cas9 system. For this study, four different exogenous DNA fragments were synthesized for four different genes. When injected, one exogenous DNA along with the CRISPR/Cas9 system, the average integration efficiency of the four exogenous DNA fragments was 35% in the embryo. Another exogenous DNA, which was longer than other four DNA fragments showed 15.6% integration efficiency. The embryos injected with the long exogenous DNA fragment, along with the CRISPR/Cas9 system, were transferred into surrogate pigs. The result was that a total of 7 piglets were born, but the exogenous DNA sequence was not found in none of the seven piglets. In conclusion, the CRISPR/Cas9 system showed effective removal of the entire gene function of specific genes in the pig. However, for future application in the human and other species, some problems (un-wanted region mutation and low efficiency of exogenous DNA integration) continue to emerge and need to be addressed in future experiments.

Le paludisme demeure une des maladies infectieuses les plus meurtrières au monde. Propagé par la piqûre d’un moustique femelle du genre Anopheles, le parasite du paludisme (Plasmodium) migre dans la circulation sanguine et infecte les cellules hépatiques de la victime. Dans le foie, le parasite se différencie et se reproduit par schizogonie à l’intérieur d’une vacuole parasitophore pour compléter la production de plusieurs milliers de mérozoïtes par cellule hépatique infectée. Ces mérozoïtes sont par la suite libérés dans la circulation sanguine où ils infectent les érythrocytes circulants dans lesquels le parasite subit des cycles d’infection, réplication et libération (processus de sortie actif provoqué par le parasite). Ces cycles répétitifs dans le sang sont à l’origine des symptômes cliniques de la maladie.Des études sur Plasmodium falciparum ont montré que P. falciparum SUB1 (PfSUB1), une protéase à sérine de la famille des subtilisines, est relâchée à l’intérieur de la vacuole parasitophore peu avant la libération des mérozoïtes des hématies. A l’intérieur de cette vacuole, la protéase intervient dans la maturation de protéines membres de la famille des SERA (famille de protéines du type papaïne) ainsi qu’un certain nombre de protéines de surface du mérozoïte (famille des MSP). Un grand intérêt a été porté sur cette protéase, car l’inhibition pharmacologique de l’activité de PfSUB1 bloque le processus de sortie et d’invasion des mérozoïtes dans le stade érythrocytaire du parasite in vitro.Le stade hépatique du parasite est une cible idéale pour le développement de traitements prophylactiques antipaludiques, car il précède la phase symptomatique de la maladie. En conséquence, il est important de mieux comprendre les mécanismes de fonctionnement du parasite à ce stade. Le présent projet avait pour but principal d’effectuer une étude du rôle de SUB1 dans le stade hépatique de Plasmodium. Pour ce faire, ce travail s’est effectué sur l’orthologue de PfSUB1 chez le parasite murin P. berghei. Dans un premier temps, l’expression de PbSUB1 dans les stades hépatiques du parasite a été confirmée en utilisant des anticorps spécifiques et en générant une lignée mutante de P. berghei exprimant la protéine endogène fusionnée à un marqueur hémagglutinine. Par la suite, l’enzyme a été exprimée sous forme recombinante et sa fonction et spécificité ont été partiellement caractérisées. Ce travail confirma que la protéase est capable de cliver des peptides basés sur les séquences de PbMSP1 et PbSERA3, substrats potentiels exprimés dans les stades hépatiques du parasite. Finalement, afin de mieux caractériser la fonction de PbSUB1, deux approches récentes permettant d’effectuer un knock-out conditionnel chez P. berghei ont été testées: le système Tet et la mutagenèse conditionnelle Flp/FRT. Afin d’utiliser cette dernière approche, une nouvelle méthode pour insérer des sites de reconnaissances Flp (sites FRT) dans les régions intergéniques de clones (dans ce cas, un clone comprenant pbsub1 et gènes voisins) provenant d’une bibliothèque génomique de P. berghei a été développée. Pour ce faire, plusieurs techniques d’ingénierie moléculaire ont été utilisées. Ces techniques, basées sur les systèmes de recombinaison de la levure (recombinase Flp) et de phages (recombineering) similaire à ceux utilisés par le projet PlasmoGEM (Pfander et al., 2012), surmontent les problèmes rencontrés par les méthodes conventionnelles pour le placement des sites FRT et sont aussi applicables aux longues séquences codantes. Avec ces nouveaux outils, un knock-out conditionnel de pbsub1 a été généré avec succès in vivo où la délétion du gène est accompagnée de l’expression d’un gène rapporteur (GFP) afin de faciliter l’identification des parasites ayant perdu le gène d’intérêt. A la fin de ce travail, une analyse préliminaire de ces parasites déficients en PbSUB1 suggère un rôle essentiel de cette protéase dans le développement de la phase hépatique du parasite. / Malaria remains one of the deadliest infectious diseases in the world. Propagated by the bite of an infected female Anopheles mosquito, the malaria parasite (Plasmodium) enters the bloodstream and infects hepatocytes. In the liver, the parasite differentiates and reproduces by schizogony within a membrane-bound parasitophorous vacuole (PV) resulting in the production of several thousands of merozoites per infected hepatic cell. These parasites are subsequently released into the blood stream where they infect circulating red blood cells and undergo repetitive cycles of infection, replication, and egress (active release of parasites) which are responsible for the clinical symptoms of the disease.Work on P. falciparum, has shown that P. falciparum SUB1 (PfSUB1), a serine protease of the subtilisin-like family, is discharged into the PV just prior to egress from the erythrocyte and mediates the proteolytic maturation of members of the SERA family (a family of papain-like proteins) as well as a number of merozoite surface proteins (MSPs). Pharmacological inhibition of PfSUB1 activity inhibits both egress and invasion of released merozoites in blood stages in vitro.The liver stage of the parasite is an ideal target for development of prophylactic anti-malarial drugs, as it is clinically silent. It is thus of importance to gain more detailed knowledge about parasite development in this stage. The main aim of this project was to study the role of SUB1 in the liver stage of the parasite life cycle. The work was performed on the orthologue of PfSUB1 in the murine malaria species P. berghei. Initially, expression of PbSUB1 in liver stages was confirmed using specific antibodies and by generating a transgenic P. berghei clone expressing epitope-tagged PbSUB1. Next, recombinant enzymatically-active PbSUB1 was expressed in insect cells and partially characterised with respect to its function and substrate specificity. This confirmed that the protease is able to process substrates based on PbMSP1 and PbSERA3, two putative substrates expressed in late hepatic stages of the parasite.Finally, to further study PbSUB1 function, two conditional gene knock-out approaches were applied to study the phenotypic consequences of loss of PbSUB1 expression. Working from a ~10 kb genomic DNA library clone comprising pbsub1 and flanking genes, a method to insert Flp recombinase recognition (FRT) sites into intergenic regions was developed. This was achieved by combining inducible Flp activation in E. coli with recombinase mediated engineering techniques similar to those that underlie the PlasmoGEM project (Pfander et al., 2012). This strategy overcomes challenges of existing techniques and is also suitable for flanking large genes with FRT sites. With these newly generated tools, an inducible knock-out of pbsub1 was successfully generated in vivo, in which stage-specific excision of the gene was accompanied by concomitant induction of GFP expression, facilitating identification of the knock-out parasites. A preliminary analysis of these PbSUB1-deficient parasites suggests an essential role for the protease in the development of liver stage schizonts.